Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447861 · ClinicalTrials.gov registry record
The 3q29 Deletion and 3q29 Duplication: Architecture of Behavioral Phenotypes
A clinical trial of Microdeletion 3q29 Syndrome and Microduplication 3q29 Syndrome, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- 800
- Enrollment target
- 1
- Study location
NCT02447861: Recruiting study of Microdeletion 3q29 Syndrome and Microduplication 3q29 Syndrome, sponsored by Rutgers, The State University of New Jersey.
NCT02447861 is a study of Microdeletion 3q29 Syndrome and Microduplication 3q29 Syndrome that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 800 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02447861, a study of Microdeletion 3q29 Syndrome and Microduplication 3q29 Syndrome, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
The 3q29 deletion syndrome is caused by a deletion of a small part of human chromosome 3, and the duplication syndrome is caused by a duplication of this same small region. The purpose of this study is to understand the medical and behavioral consequences of these syndromes.
Primary Outcome
A medical questionnaire designed to collect data on commonly reported medical conditions associated with the 3q29 deletion or duplication will be administered.
Conditions Studied
Study Locations (1)
New Jersey
- Internet-Based - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2013-07 |
| Est. Completion | 2028-01 |
What NCT02447861 shows while recruiting
NCT02447861 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Microdeletion 3q29 Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT02447861 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02447861 about?
NCT02447861 is a clinical study titled "The 3q29 Deletion and 3q29 Duplication: Architecture of Behavioral Phenotypes". The 3q29 deletion syndrome is caused by a deletion of a small part of human chromosome 3, and the duplication syndrome is caused by a duplication of this same small region. The purpose of this study is to understand the medical and behavioral consequences of these syndromes.
What is the current status of trial NCT02447861?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2013-07. Estimated completion is 2028-01.
What conditions does trial NCT02447861 study?
This clinical trial studies the following conditions: Microdeletion 3q29 Syndrome, Microduplication 3q29 Syndrome.
Who is sponsoring clinical trial NCT02447861?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02447861 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia